Literature DB >> 16732297

Permeability properties of tumor surrogate blood vessels induced by VEGF-A.

Janice A Nagy1, Dian Feng, Eliza Vasile, Wendy H Wong, Shu-Ching Shih, Ann M Dvorak, Harold F Dvorak.   

Abstract

Malignant tumors generate new blood vessels by secreting growth factors, particularly members of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) family. Overall, the new blood vessels that form are hyperpermeable to plasma proteins, a property that is thought to be important for generating new stroma. However, tumor blood vessels are structurally heterogeneous and include microvessels of at least the following distinct types: mother vessels (MV), glomeruloid microvascular proliferations (GMP), arterio-venous-like vascular malformations and capillaries. Our goal was to determine whether macromolecular tracers leaked from all or from only a subset of these vessel types and to elucidate the extravasation pathways. As blood vessels are only a minor component of tumors, and therefore, difficult to study in situ, we used an adenoviral vector to express VEGF-A164, the most important member of the VPF/VEGF family, in mouse tissues. So expressed, VEGF-A164 induces large numbers of surrogate vessels of each type found in tumors in a highly reproducible manner. Overall permeability to plasma proteins was assessed qualitatively with Evan's blue dye and quantitatively with a dual tracer method employing radioactive albumin. Leaky vessels were identified by confocal microscopy (FITC-dextran) and by electron microscopy (ferritin). MV, and to a lesser extent GMP, were found to be hyperpermeable but capillaries and vascular malformations were not. Ferritin extravasated primarily by two trans-cellular routes, vesiculo-vacuolar organelles (VVOs) and fenestrae. This occurred despite a considerable reduction in VVO frequency as VVO membranes translocated to the plasma membrane during MV formation. However, reduction in the number and complexity of VVOs was offset by extensive endothelial cell thinning and a greatly shortened extravasation pathway. Extrapolating these findings to tumors predicts that only a subset of tumor vessels, MV and GMP, is hyperpermeable, and that measures of overall vessel permeability greatly underestimate the permeability of individual MV and GMP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732297     DOI: 10.1038/labinvest.3700436

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  49 in total

1.  DEP induction of ROS in capillary-like endothelial tubes leads to VEGF-A expression.

Authors:  Ming Wei Chao; Iris P Po; Robert J Laumbach; John Koslosky; Keith Cooper; Marion K Gordon
Journal:  Toxicology       Date:  2012-04-07       Impact factor: 4.221

2.  Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.

Authors:  Napoleone Ferrara
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

3.  Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1.

Authors:  Mien V Hoang; Janice A Nagy; Donald R Senger
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 4.  Restoring the renal microvasculature to treat chronic kidney disease.

Authors:  David A Long; Jill T Norman; Leon G Fine
Journal:  Nat Rev Nephrol       Date:  2012-02-07       Impact factor: 28.314

5.  Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction.

Authors:  Lior Zangi; Kathy O Lui; Alexander von Gise; Qing Ma; Wataru Ebina; Leon M Ptaszek; Daniela Später; Huansheng Xu; Mohammadsharif Tabebordbar; Rostic Gorbatov; Brena Sena; Matthias Nahrendorf; David M Briscoe; Ronald A Li; Amy J Wagers; Derrick J Rossi; William T Pu; Kenneth R Chien
Journal:  Nat Biotechnol       Date:  2013-09-08       Impact factor: 54.908

6.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Linus Lee; Meredith A Jackson; Kameron V Kilchrist; Dana Brantley-Sieders; Craig L Duvall
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

7.  Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.

Authors:  Basel Sitohy; Sunghee Chang; Tracey E Sciuto; Elizabeth Masse; Mei Shen; Peter M Kang; Shou-Ching Jaminet; Laura E Benjamin; Rupal S Bhatt; Ann M Dvorak; Janice A Nagy; Harold F Dvorak
Journal:  Am J Pathol       Date:  2017-07-21       Impact factor: 4.307

8.  Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.

Authors:  Alessandro Prete; Agnes S Lo; Peter M Sadow; Swati S Bhasin; Zeus A Antonello; Danica M Vodopivec; Soumya Ullas; Jennifer N Sims; John Clohessy; Ann M Dvorak; Tracey Sciuto; Manoj Bhasin; Joanne E Murphy-Ullrich; Jack Lawler; S Ananth Karumanchi; Carmelo Nucera
Journal:  Clin Cancer Res       Date:  2018-08-03       Impact factor: 12.531

9.  Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo.

Authors:  Ivy Chung; Guangzhou Han; Mukund Seshadri; Bryan M Gillard; Wei-dong Yu; Barbara A Foster; Donald L Trump; Candace S Johnson
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

10.  High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish.

Authors:  Konstantin Stoletov; Valerie Montel; Robin D Lester; Steven L Gonias; Richard Klemke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.